Everolimus
- Generic Name
- Everolimus
- Brand Names
- Afinitor, Votubia, Zortress
- Drug Type
- Small Molecule
- Chemical Formula
- C53H83NO14
- CAS Number
- 159351-69-6
- Unique Ingredient Identifier
- 9HW64Q8G6G
- Background
Everolimus is a derivative of Rapamycin (sirolimus), and works similarly to Rapamycin as an mTOR (mammalian target of rapamycin) inhibitor. It is currently used as an immunosuppressant to prevent rejection of organ transplants. In a similar fashion to other mTOR inhibitors Everolimus' effect is solely on the mTORC1 protein and not on the mTORC2 protein.
- Indication
Everolimus is indicated for the treatment of postmenopausal women with advanced hormone receptor-positive, HER2-negative breast cancer (advanced HR+ BC) in combination with exemestane, after failure of treatment with letrozole or anastrozole.
Indicated for the treatment of adult patients with progressive neuroendocrine tumors of pancreatic origin (PNET) with unresectable, locally advanced or metastatic disease.
Indicated for the treatment of adult patients with advanced renal cell carcinoma (RCC) after failure of treatment with sunitinib or sorafenib.
Indicated for the treatment of adult patients with renal angiomyolipoma and tuberous sclerosis complex (TSC), not requiring immediate surgery.
Indicated in pediatric and adult patients with tuberous sclerosis complex (TSC) for the treatment of subependymal giant cell astrocytoma (SEGA) that requires therapeutic intervention but cannot be curatively resected.
- Associated Conditions
- Heart Transplant Rejection, Kidney Transplant Rejection, Liver Transplant Rejection, Progressive Neuroendocrine Tumors of pancreatic origin, Renal angiomyolipoma, tuberous sclerosis complex, Subependymal giant cell astrocytoma, tuberous sclerosis complex, Waldenstrom's Macroglobulinemia Refractory, Advanced Carcinoid tumor, Locally advanced Progressive Neuroendocrine Tumors of gastrointestinal origin, Locally advanced lung origin Progressive Neuroendocrine Tumors, Metastatic gastrointestinal origin Progressive Neuroendocrine Tumors, Metastatic lung origin Progressive Neuroendocrine Tumors, Refractory Advanced Renal Cell Carcinoma, Refractory, advanced Breast cancer, Unresectable gastrointestinal origin Progressive Neuroendocrine Tumors, Unresectable lung origin Progressive Neuroendocrine Tumors
- Associated Therapies
- -
ARN 509 Plus Everolimus in Men With Progressive Metastatic Castration-Resistant Prostate Cancer After Treatment With Abiraterone Acetate
- First Posted Date
- 2014-04-08
- Last Posted Date
- 2023-05-26
- Lead Sponsor
- Memorial Sloan Kettering Cancer Center
- Target Recruit Count
- 9
- Registration Number
- NCT02106507
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
Novartis Everolimus Transition
- Conditions
- Interventions
- First Posted Date
- 2014-03-26
- Last Posted Date
- 2018-08-08
- Lead Sponsor
- Medical University of South Carolina
- Target Recruit Count
- 60
- Registration Number
- NCT02096107
- Locations
- 🇺🇸
Medical University of South Carolina, Charleston, South Carolina, United States
MicroRNA Expression in Everolimus-based Versus Tacrolimus-based Regimens in Kidney Transplantation
- First Posted Date
- 2014-03-19
- Last Posted Date
- 2014-03-19
- Lead Sponsor
- Chulalongkorn University
- Target Recruit Count
- 50
- Registration Number
- NCT02091973
- Locations
- 🇹🇭
Chulalongkorn University, Bangkok, Thailand
Everolimus + Very Low Tacrolimus vs Enteric-coated Mycophenolate Sodium + Low Tacrolimus in de Novo Renal Transplant
- First Posted Date
- 2014-03-12
- Last Posted Date
- 2019-02-22
- Lead Sponsor
- Ronaldo de Matos Esmeraldo, MD
- Target Recruit Count
- 120
- Registration Number
- NCT02084446
- Locations
- 🇧🇷
Hospital Geral de Fortaleza, Fortaleza, Ceará, Brazil
Safety and Efficacy of Everolimus Treatment in Liver Transplantation for Liver Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-03-07
- Last Posted Date
- 2024-01-30
- Lead Sponsor
- Baylor Research Institute
- Target Recruit Count
- 336
- Registration Number
- NCT02081755
- Locations
- 🇺🇸
Washington University School of Medicine, Saint Louis, Missouri, United States
🇺🇸Mayo Clinic, Rochester, Minnesota, United States
🇺🇸Northwestern University School of Medicine, Chicago, Illinois, United States
Study of Safety and Efficacy of Alpelisib With Everolimus or Alpelisib With Everolimus and Exemestane in Advanced Breast Cancer Patients, Renal Cell Cancer and Pancreatic Tumors
- Conditions
- Interventions
- First Posted Date
- 2014-03-04
- Last Posted Date
- 2020-12-08
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 79
- Registration Number
- NCT02077933
- Locations
- 🇬🇧
Novartis Investigative Site, Manchester, United Kingdom
🇺🇸Memorial Sloan Kettering Cancer Center SC - BYL719Z2102, New York, New York, United States
🇺🇸Highlands Oncology Group, Fayetteville, Arkansas, United States
Effect of Everolimus on the Pharmacokinetics of Tacrolimus in Renal Transplant Patients
- Conditions
- Interventions
- First Posted Date
- 2014-03-04
- Last Posted Date
- 2019-07-24
- Lead Sponsor
- National Taiwan University Hospital
- Target Recruit Count
- 14
- Registration Number
- NCT02077556
- Locations
- 🇨🇳
National Taiwan University Hospital, Taipei, Taiwan
Open-label, Phase II Study of Stomatitis Prevention With a Steroid-based Mouthwash in Post-menopausal Women With Estrogen-receptor-positive (ER+), Human Epidermal Growth Factor Receptor 2 (HER2)- Metastatic or Locally Advanced Breast Cancer
- Conditions
- Interventions
- First Posted Date
- 2014-02-21
- Last Posted Date
- 2017-02-13
- Lead Sponsor
- Novartis Pharmaceuticals
- Target Recruit Count
- 92
- Registration Number
- NCT02069093
- Locations
- 🇺🇸
Regional Cancer Care Associates Cancer and Hematologic Disease, Cherry Hill, New Jersey, United States
🇺🇸Hematology Oncology Associates of Northern New Jersey PA DeptofHem-OncofNorthern NJ (2), Morristown, New Jersey, United States
🇺🇸Highlands Oncology Group Highlands Oncology Group (22), Fayetteville, Arkansas, United States
Differentiating Everolimus Versus Sirolimus in Combination With Calcineurin Inhibitors in Kidney Transplant Patients
- First Posted Date
- 2014-02-14
- Last Posted Date
- 2014-12-02
- Lead Sponsor
- University of Colorado, Denver
- Registration Number
- NCT02062892
A Study of LY2835219 (Abemaciclib) in Combination With Therapies for Breast Cancer That Has Spread
- First Posted Date
- 2014-02-06
- Last Posted Date
- 2024-08-28
- Lead Sponsor
- Eli Lilly and Company
- Target Recruit Count
- 198
- Registration Number
- NCT02057133
- Locations
- 🇺🇸
Memorial Sloan Kettering Cancer Center, New York, New York, United States
🇺🇸Highlands Oncology Group - Duplicate 2, Rogers, Arkansas, United States
🇺🇸Vanderbilt University Medical Center, Nashville, Tennessee, United States
Drug Development Updates
Stay informed with timely notifications on clinical trials, regulatory changes, and research advancements related to this medication.